© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
NSCLC
Three Studies of Lung Cancer Patients with METex14 Skipping Mutation Presented at ASCO
June 24, 2021
Positive findings for Tepmetko and Tabrecta reported at ASCO.
ASCO 2021: Lumakras, First Approved KRAS-targeting Cancer Drug, Looks Promising
June 04, 2021
The FDA approved Amgen’s Lumakras (sotorasib) last week, the first drug targeting KRAS-mutated cancer to get the agency’s OK. But the clinical and commercial future of the drug is uncertain.
Black Lung Cancer Patients May Be Missing Out On Era of Targeted Therapy
June 01, 2021
Meta-analysis shows lower prevalence of four known driver mutations among Black lung cancer patients. More research into tumor biology of Black patients might yield targeted therapies that would benefit Black lung cancer patients, says the lead author, Philippos A. Costa, M.D.
Atezolizumab Extends Disease-Free Survival in Patients with PD-L1 Positive Early NSCLC
June 01, 2021
Patients who were PD-L1 positive with early stage non-small-cell lung cancer had better results and a lower risk of death or progression compared to a cohort on best supportive care.
FDA Approves Drug Targeting KRAS Mutation For First Time
May 28, 2021
The FDA gave its first approval today of a cancer drug that targets a KRAS mutation.
FDA Approves J&J's Rybrevant for NSCLC With Certain Kind of EGFR Mutation
May 21, 2021
Precision medicine is getting that much more precise. Today's FDA go-ahead is for a J&J drug that is designed to treat the 2% to 3% of NSCLC patients wiht EGFR exon 20 insertion mutations.
NSCLC Care That Doesn’t Follow NCCN Guidelines is 27% More Costly
May 21, 2021
CVS Health research shows $7,084 cost disadvantage to care that is not "concordant" with National Comprehensive Care Network guidelines.
Lung Cancer Screening Has Had Few Takers. Will Updated Recommendations Make a Difference?
May 20, 2021
A small fraction of those who were eligible under previous U.S. Preventive Services Task Force recommendations were screened with low-dose CT scans. New recommendations will make an additional 6.4 million Americans eligible, but a number of barriers to screening remain.
How the Menthol Cigarette Ban May Affect the African American Smoking Paradox
May 05, 2021
The prevalence of smoking among African American young adults “catches up” with other groups despite the low rate among Black youth. The ban on menthol may affect this and other aspects of smoking patterns among Black Americans.
KRAS Mutation Could Guide Treatment Decisions in Nonsmall Cell Lung Cancer
May 04, 2021
Chemo in combination with immunotherapy was preferable to immunotherapy alone in patients with a mutation of the KRAS gene and high levels of programmed cell death ligand 1, according to findings reported in JAMA Oncology.